Chronic Obstructive Pulmonary Disease

The answer first

COPD is a common, preventable and treatable disease characterised by persistent respiratory symptoms and airflow limitation caused by airway and alveolar abnormalities, usually driven by significant exposure to noxious particles or gases — overwhelmingly tobacco smoke. The diagnosis is confirmed by spirometry: a post-bronchodilator FEV1/FVC ratio less than 0.70. [1]

Two facts must land before everything else: [1]

1. COPD is not asthma. Inhaled corticosteroids (ICS) are not first-line monotherapy in COPD. The cornerstone of pharmacotherapy is bronchodilation — a long-acting muscarinic antagonist (LAMA) and/or long-acting beta-agonist (LABA). ICS is added only when exacerbations persist despite dual bronchodilation, and its use carries a real pneumonia risk.
2. Exacerbations drive mortality and decline. A hospital admission for an exacerbation marks a step-change in the disease trajectory. Preventing exacerbations — through bronchodilation, smoking cessation, vaccination, pulmonary rehabilitation, and oxygen where indicated — is the central goal of long-term management. [1]

The two interventions with proven mortality benefit are smoking cessation and long-term oxygen therapy (LTOT) for severe chronic hypoxaemia. No inhaled drug has convincingly reduced all-cause mortality — but they reduce exacerbations, improve symptoms, and slow decline. [1]

---

Classification

Step 1: Confirm the diagnosis

Spirometry is mandatory and must be post-bronchodilator (after 400 mcg salbutamol or equivalent): [1]

• FEV1/FVC less than 0.70 confirms persistent airflow obstruction → COPD.
• If FEV1/FVC is at least 0.70, the patient does not have COPD by spirometric criteria regardless of symptoms. [1]

DWE trap: Spirometry must be interpreted in the clinical context. A fixed ratio of 0.70 overdiagnoses COPD in the elderly (where the normal ratio falls with age) and may underdiagnose it in young patients. The lower limit of normal (LLN) is more accurate but the 0.70 cutoff remains the pragmatic GOLD standard for exams. [1]

Step 2: Grade airflow limitation severity (GOLD 1-4)

Once obstruction is confirmed, severity is graded by FEV1 percent predicted (not the ratio): [1]

Examiner point: FEV1 alone does not determine therapy. GOLD moved away from using spirometric stage alone to guide treatment because symptoms and exacerbation history matter more than the FEV1 number for management decisions. [1]

Step 3: Assess symptom burden and exacerbation risk (GOLD ABE)

The GOLD ABE tool (2024) classifies patients by symptoms (mMRC or CAT) and exacerbation history to drive initial therapy: [1]

mMRC dyspnoea scale (modified Medical Research Council): [1]

DCE trap: Always state the patient's mMRC grade, GOLD stage, and ABE group in your long-case opening. This demonstrates you understand that COPD severity is multidimensional, not just an FEV1 number. [1]

---

Pathophysiology

COPD has two anatomically overlapping but mechanistically distinct processes: small airway disease (chronic bronchiolitis with fibrosis and narrowing) and parenchymal destruction (emphysema with loss of alveolar attachments). Both produce airflow limitation, but through different mechanisms. [1]

Chronic inflammation

Cigarette smoke activates macrophages and epithelial cells, which recruit neutrophils, CD8+ T-cells, and macrophages into the airway wall and alveoli. Unlike asthma (eosinophilic, CD4+ Th2-driven), COPD inflammation is predominantly neutrophilic. This inflammation persists even after smoking cessation — the fire is lit and does not fully extinguish. [1]

Protease-antiprotease imbalance

Activated neutrophils and macrophages release proteases — neutrophil elastase, matrix metalloproteinases (MMPs), cathepsins. These digest the elastin-rich alveolar extracellular matrix. Normally, alpha-1-antitrypsin (AAT) — a protease inhibitor (Pi) produced by the liver — neutralises elastase and protects the parenchyma. When the protease burden overwhelms the antiprotease defence (smoking) or the antiprotease is genetically deficient (AAT deficiency), irreversible emphysematous destruction follows. [1]

DWE high-yield: Alpha-1-antitrypsin deficiency is an autosomal codominant condition. The PiZZ genotype (severe deficiency) causes panlobular (panacinar) emphysema with basal predominance (unlike smoking's centrilobular apical pattern), often presenting under age 45, and may coexist with liver disease (misfolded AAT accumulates in hepatocytes). Test the serum AAT level (and genotype if low) in: age under 45, basilar emphysema, family history, or COPD in a never-smoker. [1]

Loss of elastic recoil and dynamic hyperinflation

Emphysematous destruction destroys the alveolar attachments that tether small airways open. During expiration — especially with increased respiratory drive (exertion, exacerbation) — the unsupported airways collapse prematurely, trapping gas. The lungs hyperinflate. This dynamic hyperinflation pushes the diaphragm into a flattened, mechanically disadvantaged position; the patient breathes at a higher lung volume where the respiratory muscles are inefficient. This is why exertional dyspnoea in COPD is driven by the mechanical load on respiratory muscles, not just FEV1. Pursed-lip breathing — a learned compensatory behaviour — slows expiration and keeps airways open longer, reducing gas trapping. [1]

Gas exchange failure

Two mechanisms produce the characteristic blood gas abnormalities: [1]

• V/Q mismatch from airway obstruction and alveolar destruction causes type 1 respiratory failure (hypoxia with normal/low CO2) in milder disease.
• In advanced disease, ventilatory failure — the combination of severe mechanical load, respiratory muscle fatigue, and blunted central drive — produces type 2 respiratory failure (hypoxia with CO2 retention and respiratory acidosis). [1]

Hypoxic pulmonary vasoconstriction chronically narrows the pulmonary arteriolar bed, causing pulmonary hypertension. Over years this leads to right ventricular hypertrophy and cor pulmonale (right heart failure from a pulmonary cause). [1]

Why does giving too much oxygen harm a COPD patient? Two mechanisms: (1) the Haldane effect — oxygenating haemoglobin reduces its CO2-carrying capacity, raising PaCO2; (2) V/Q mismatch worsens — oxygen relieves hypoxic vasoconstriction in poorly ventilated units, increasing shunt (perfusion without ventilation). This is why controlled, titrated oxygen (target SpO2 88-92%) is mandatory in COPD with possible CO2 retention. [1]

---

Clinical presentation

Chronic bronchitis vs emphysema phenotypes

These are phenotypic patterns, not separate diseases. Most patients have elements of both, but recognising the dominant phenotype guides expectations: [1]

Examiner caveat: The "blue bloater / pink puffer" dichotomy is a teaching heuristic, not a rigid classification. Real patients overlap. Use it to illustrate that chronic bronchitis patients retain CO2 and develop cor pulmonale earlier, while emphysema patients maintain near-normal gases longer but are more breathless. [1]

Symptoms

• Exertional dyspnoea — the cardinal symptom; progressive, often attributed to "ageing" or "unfitness" until advanced
• Chronic cough — often the earliest symptom; typically worse in the morning
• Sputum production — mucoid; purulence during exacerbation
• Wheeze and chest tightness
• Fatigue, weight loss, muscle wasting (sarcopenia) — systemic effects of chronic inflammation
• Ankle swelling — cor pulmonale [1]

Signs (elicit systematically in the short case)

• Body habitus: thin/cachectic (emphysema) or oedematous (cor pulmonale)
• Breathing pattern: pursed-lip breathing, use of accessory muscles (sternocleidomastoid, scalenes), intercostal indrawing, tripod position
• Chest: barrel chest (increased AP diameter), hyper-resonance to percussion, reduced air entry, prolonged expiration, expiratory wheeze
• Breath sounds: distant vesicular sounds, rhonchi/wheeze; coarse crackles may indicate coexisting infection or bronchiectasis
• Cor pulmonale signs: elevated JVP, right ventricular heave, loud pulmonary component of S2 (P2), tricuspid regurgitation murmur (pansystolic, lower left sternal edge, louder on inspiration), peripheral oedema, hepatomegaly
• Cyanosis (central — blue lips/tongue), clubbing (if present, question the diagnosis — COPD alone does not cause clubbing; look for lung cancer, bronchiectasis, or ILD)
• Tremor and palpitations — beta-agonist side effects; asterixis — CO2 retention [1]

DCE short-case trap: Clubbing is NOT a feature of uncomplicated COPD. If you find clubbing in a "COPD" patient, actively seek an alternative diagnosis — lung cancer (the commonest cause in a smoker), bronchiectasis, idiopathic pulmonary fibrosis. This is a classic PACES discriminator. [1]

---

Differential diagnosis

Asthma-COPD overlap (ACO): When a patient has features of both (e.g., a lifelong smoker with atopy, partially reversible obstruction, and eosinophilia), treat the dominant treatable trait. These patients often benefit more from ICS than pure COPD patients. [1]

DWE high-yield discrimination: The single most useful distinguishing test is the bronchodilator response. Asthma shows significant reversibility (FEV1 increase of at least 12% and 200 mL); COPD shows partial or no reversibility. But a partial response in COPD does not make it asthma — many COPD patients have some reversibility. [1]

---

Investigations

Essential for every patient

Selected investigations (based on clinical context)

The BODE index — multidimensional prognostic tool

FEV1 alone underestimates the systemic nature of COPD. The BODE index (Body-mass index, Obstruction, Dyspnoea, Exercise capacity) is a far better predictor of mortality than FEV1 alone [11]:

Total score 0-10. A higher BODE score predicts worse survival: a BODE score of 7-10 carries an approximate 80% 4-year mortality, versus near-normal survival for scores of 0-2. [1]

DCE long-case point: Calculate and state the BODE score. This shows the examiner you understand that a COPD patient's prognosis — and therefore the urgency of interventions like pulmonary rehabilitation and advance care planning — depends on more than the FEV1. [1]

---

Management of stable COPD

Management has four pillars: smoking cessation, pharmacotherapy, pulmonary rehabilitation, and oxygen/NIV where indicated. Each addresses a different goal — symptom relief, exacerbation prevention, mortality reduction, or functional improvement. [1]

Pillar 1: Smoking cessation — the only disease-modifying intervention

Smoking cessation is the single most effective and cost-effective intervention. It slows the rate of FEV1 decline (the Lung Health Study showed the decline rate halves) and is one of only two interventions with a mortality signal. [1]

• 5 As framework: Ask, Advise, Assess, Assist, Arrange.
• Pharmacotherapy:
  • Varenicline (nicotine receptor partial agonist) — most effective single agent; course 12 weeks. Concerns about neuropsychiatric and cardiovascular adverse events were not borne out by the EAGLES trial.
  • Nicotine replacement therapy (NRT) — combination patch plus short-acting form is most effective.
  • Bupropion — less effective; avoids weight gain; contraindicated in seizure/eating disorders.
• Behavioural support combined with pharmacotherapy gives the best quit rates. [1]

Pillar 2: Pharmacotherapy — bronchodilation first

When to use ICS — the eosinophil-guided approach

ICS is not routine in COPD. It increases pneumonia risk (number needed to harm ~20 over 3 years in TORCH-like populations). Use ICS when: [1]

• Blood eosinophils at least 300/microL — strongest predictor of ICS response (asthma-like biology).
• Frequent exacerbations (2 or more moderate, or 1 hospitalisation) despite LAMA/LABA — add ICS as triple therapy.
• Asthma-COPD overlap — ICS is essential (the patient has asthma). [1]

Consider withdrawing ICS if eosinophils are low (less than 100) and there is no exacerbation benefit, to reduce pneumonia risk and polypharmacy. Withdrawal should be gradual. [1]

DWE high-yield contrast with heart failure: In HFrEF, more disease-modifying drugs are better. In COPD, ICS is not a "more is better" drug — it is a targeted add-on with a real downside. This is one of the most common exam traps. [1]

Pillar 3: Pulmonary rehabilitation

A structured 6-8 week program of exercise training, education, and behavioural change. It is one of the most cost-effective interventions in COPD, with evidence across all severity groups: [1]

• Reduces dyspnoea (the largest effect size of any COPD intervention on the mMRC)
• Improves exercise capacity (6MWT), quality of life
• Reduces hospital readmission and anxiety/depression after an exacerbation (start within 4 weeks of discharge) [1]

Refer all symptomatic COPD patients — it is not reserved for severe disease. [1]

Pillar 4: Oxygen therapy and domiciliary NIV

Long-term oxygen therapy (LTOT) is the second intervention with proven mortality benefit. The evidence comes from two landmark trials — NOTT [7] and the MRC trial (1981) — both showing that continuous oxygen (at least 15 hours/day) in chronically hypoxaemic COPD patients improves survival.

LTOT criteria (assess on two ABGs at least 3 weeks apart in stable clinical state on optimal therapy): [1]

Prescription: oxygen at a flow rate to maintain SaO2 at least 90% (usually 1-3 L/min), for at least 15 hours/day (including sleep time, when hypoxaemia worsens). Counselling on smoking cessation is mandatory — oxygen + cigarettes is a fire and explosion risk. [1]

Domiciliary NIV (BiPAP) is indicated for COPD patients with chronic hypercapnic respiratory failure (daytime PaCO2 greater than 50 mmHg, or nocturnal desaturation/hypercapnia despite LTOT) who have had at least one acute decompensation requiring acute NIV. It improves survival, symptoms, and PaCO2 in selected patients (home NIV is not for every COPD patient — it targets the chronic hypercapnic phenotype). [1]

Other non-pharmacological measures

• Vaccination: annual influenza; pneumococcal (conjugate then polysaccharide schedule per local guideline); COVID-19; pertussis. Vaccination prevents infection-driven exacerbations.
• Nutritional support: address cachexia/sarcopenia; low BMI worsens prognosis.
• Lung volume reduction: surgery or endobronchial valves for selected patients with severe upper-lobe-predominant emphysema and low exercise capacity — improves FEV1, symptoms, and survival in carefully selected patients.
• Lung transplant: for very severe COPD meeting transplant criteria.
• Advance care planning and palliative care: opioids for refractory dyspnoea; discuss goals of care in advanced disease. [1]

---

Acute exacerbation of COPD (AECOPD)

An exacerbation is an acute worsening of respiratory symptoms beyond day-to-day variation that warrants a change in therapy. Exacerbations accelerate FEV1 decline, impair quality of life, and are a major mortality driver. [1]

Causes and precipitants

DCE trap: In a COPD patient who deteriorates unexpectedly or fails to improve on standard therapy, reconsider the diagnosis of a simple exacerbation. Actively exclude pneumothorax (examine and image), pulmonary embolism (consider D-dimer/CTPA if risk factors), and cardiac causes (ECG, troponin). Missing a PE or pneumothorax in a breathless COPD patient is a classic and dangerous error. [1]

Assessment

• History: change in dyspnoea, sputum volume, sputum purulence, fever, chest pain (pleuritic = PE/pneumothorax/infection), duration, prior exacerbation/intubation history
• Examination: respiratory rate, work of breathing, use of accessory muscles, cyanosis, confusion (hypercapnia), signs of cor pulmonale, oxygen saturation
• Anthonisen criteria (guide the decision to give antibiotics):
  • Increased dyspnoea
  • Increased sputum volume
  • Increased sputum purulence
  • Type 1 (all 3) — antibiotics clearly indicated
  • Type 2 (2 of 3) — antibiotics indicated, especially if increased purulence
  • Type 3 (1 of 3) — antibiotics not routinely needed
• Investigations: CXR (exclude pneumonia/pneumothorax), ABG (assess respiratory failure), FBE, CRP, troponin/ECG (cardiac cause), sputum culture if purulent, consider D-dimer/CTPA for PE [1]

Management of the acute exacerbation

NIV in COPD with acute type 2 respiratory failure — the evidence

This is one of the strongest evidence-based interventions in respiratory medicine. Non-invasive ventilation (BiPAP) is the first-line ventilatory support for COPD exacerbations with persistent hypercapnic respiratory failure, and it should be started early, on the ward, before ICU is needed. [1]

Indications (after optimal medical therapy for 30-60 minutes):

• pH 7.25-7.35 with PaCO2 at least 45 mmHg (6 kPa)
• OR PaCO2 at least 60 mmHg (8 kPa) with pH less than 7.35 [1]

Contraindications (relative/absolute):

• Respiratory arrest or apnoea (needs intubation)
• Cardiovascular instability (shock, uncontrolled ischaemia/arrhythmia)
• Inability to protect airway, excessive secretions, agitation/aggression
• Facial deformity/trauma precluding mask fit
• Severe encephalopathy (GCS less than 8) — but mild CO2-related drowsiness improves on NIV [1]

Practical settings (BiPAP — bilevel positive airway pressure):

• IPAP (inspiratory positive airway pressure) starts 10-12 cmH2O, titrate up by 2 cmH2O to 20 cmH2O to reduce PaCO2 and relieve work of breathing
• EPAP (expiratory positive airway pressure) 4-5 cmH2O
• FiO2 titrated to SpO2 88-92%
• Reassess ABG at 1-2 hours; adjust IPAP [1]

Outcome benefit (Plant et al.): compared with standard therapy alone, adding early ward-based NIV halved intubation rates (15% vs 27%) and halved in-hospital mortality (10% vs 20%). This is a mortality-reducing, cost-saving, ward-delivered intervention — know these numbers for the exam [4].

DWE high-yield: "When would you intubate a COPD patient instead of continuing NIV?" Answer: NIV failure — persistent or worsening acidosis (pH less than 7.25) despite optimised NIV over 1-4 hours, deteriorating consciousness, respiratory arrest, or haemodynamic instability. Intubation in severe COPD carries a higher mortality than in many other causes of respiratory failure, which is exactly why NIV is so important — but do not delay intubation when NIV has clearly failed. [1]

---

Comorbidities

COPD is a systemic disease. Comorbidities are common, independently worsen prognosis, and must be actively managed — they are not optional extras in the long case. [1]

DCE long-case point: In the comorbidity discussion, explicitly name each comorbidity and your management plan. Examiners are testing whether you treat the whole patient, not just the lungs. A COPD long case that omits osteoporosis, depression, and cardiovascular risk is incomplete. [1]

---

Prognosis

• COPD is the third leading cause of death worldwide.
• Median survival from diagnosis depends heavily on severity and comorbidity. GOLD 4 patients with a hospitalising exacerbation have a 1-year mortality of ~20-30%.
• Key prognostic markers: BODE index (best single multidimensional predictor), FEV1, 6MWT distance, PaO2, BMI, exacerbation frequency, cor pulmonale.
• Smoking cessation and LTOT are the two mortality-reducing interventions.
• Hospitalisation for exacerbation marks a turning point — post-hospitalisation mortality is high; early pulmonary rehabilitation and optimised maintenance therapy reduce readmission. [1]

---

DCE long-case approach

Opening statement (SASPOP)

"Mr Hayes is a 70-year-old retired boilermaker and 50 pack-year smoker who presents with a 6-month history of increasing exertional dyspnoea — now breathless dressing — and three hospital admissions in the past year for infective exacerbations. He was recently started on home oxygen after an ABG showed PaO2 of 52. [1]

His past history includes cor pulmonale, osteoporosis (wrist fracture last year), depression, hypertension, and a former 30 g/day alcohol intake. [1]

His medications are tiotropium, salmeterol/fluticasone, salbutamol PRN, frusemide, sertraline, alendronate, and home oxygen 2 L/min. [1]

His FEV1 is 32% predicted (GOLD 3) with an FEV1/FVC of 0.48. His BODE score is 7. His echo shows a dilated RV with estimated PASP 55 mmHg. [1]

His main problems are:

1. Severe COPD (GOLD 3, Group E) with frequent exacerbations and chronic hypoxaemia on LTOT
2. Cor pulmonale with pulmonary hypertension
3. Osteoporosis (treatment-induced and disease-related)
4. Depression
5. Ongoing tobacco dependence
6. Social isolation — lives alone, at risk of readmission" [1]

Integrated management plan

1. Respiratory: Confirm adherence and inhaler technique. He is on LAMA + ICS/LABA (effectively triple therapy). Check eosinophils — if low and no exacerbation benefit from ICS, consider ICS withdrawal to reduce pneumonia risk. Add roflumilast if chronic bronchitis phenotype with frequent exacerbations persists. Consider dual bronchodilation (LAMA/LABA) single inhaler for simplicity. Confirm LTOT prescription (at least 15 hours/day). Refer for pulmonary rehabilitation. Assess for domiciliary NIV if daytime hypercapnia. Assess for lung volume reduction if upper-lobe-predominant emphysema and low exercise capacity.
2. Cardiac/cor pulmonale: Continue frusemide for oedema (monitor electrolytes). Optimise pulmonary hypertension with oxygen (the primary therapy). Consider referral to pulmonary hypertension service if disproportionate. Screen for and manage AF.
3. Smoking cessation: Intensive support; offer varenicline; this is the single most important intervention even at this stage.
4. Vaccinations: Influenza (annual), pneumococcal, COVID-19.
5. Bone health: Continue alendronate; DEXA; calcium/vitamin D; minimise oral steroids.
6. Mental health: Treat depression (continue sertraline); screen for anxiety; pulmonary rehabilitation has psychological benefit.
7. Advance care planning: Discuss prognosis and goals of care; document ceiling of treatment; consider palliative care involvement for refractory dyspnoea (opioids). [1]

DCE examiner probing questions you must anticipate:

• "Why is he on an ICS and would you continue it?" — Eosinophil-guided; if eosinophils low, withdraw to reduce pneumonia risk.
• "His PaCO2 is 58 on room air. Would you start home NIV?" — Yes, chronic hypercapnic respiratory failure with a prior decompensation; home BiPAP improves survival and symptoms.
• "He wants to keep smoking while on home oxygen. How do you counsel him?" — Absolute fire/explosion risk; must stop smoking to continue LTOT safely; re-engage cessation support.
• "What is his prognosis?" — BODE 7 indicates a high 4-year mortality (~80%); discuss honestly and frame around maximising quality of life and functional independence. [1]

---

DCE short-case approach: respiratory examination

Instruction: "Examine this patient's respiratory system." [1]

Systematic routine

1. End of bed: Body habitus (thin/cachectic or oedematous), breathing pattern (pursed-lip, accessory muscles, tripod), cyanosis, oxygen tubing or nebuliser in situ, tremor (beta-agonist).
2. Hands: Clubbing (if present — reconsider the diagnosis), peripheral cyanosis, tremor, asterixis (CO2 retention). Pulse (rate, rhythm — AF common), respiratory rate (count discreetly).
3. Face: Conjunctival pallor, central cyanosis (under tongue, lips), plethoric facies (polycythaemia).
4. Neck: JVP (elevated in cor pulmonale), tracheal position (central; deviated with pneumonectomy/fibrosis), cricosternal distance (shortened in hyperinflation).
5. Chest inspection: Barrel chest (increased AP diameter), scars, symmetry, intercostal indrawing, Harrison's sulci.
6. Chest expansion: Reduced and symmetrical in hyperinflation; measure with tape at the 4th intercostal space.
7. Percussion: Hyper-resonant bilaterally (air trapping); dullness suggests consolidation, effusion, or collapse.
8. Auscultation: Reduced vesicular breath sounds, prolonged expiration, expiratory wheeze (polyphonic rhonchi). Coarse crackles may indicate infection or bronchiectasis. Compare zones systematically.
9. Vocal resonance/tactile fremitus: Reduced in effusion/pneumothorax; increased in consolidation.
10. Back: Chest expansion posteriorly, basal crackles (co-existent infection/oedema).
11. Cor pulmonale signs: JVP, RV heave (parasternal), loud P2, TR murmur (lower left sternal edge, louder on inspiration), peripheral/sacral oedema, hepatomegaly.
12. Legs: Deep vein thrombosis signs (calf tenderness, swelling — PE can precipitate exacerbation), peripheral oedema. [1]

Presentation template

"I examined Mr Hayes's respiratory system. He is thin, breathless at rest, and using accessory muscles with pursed-lip breathing. There is no clubbing. He has central cyanosis and a fine tremor. The respiratory rate is 24 per minute. The chest is barrel-shaped with increased anteroposterior diameter. Chest expansion is reduced bilaterally at 3 cm. Percussion note is hyper-resonant throughout. On auscultation, breath sounds are globally reduced with a prolonged expiratory phase and widespread expiratory polyphonic wheeze. [1]

The JVP is elevated 5 cm with a prominent V wave. There is a right ventricular heave. The pulmonary component of the second heart sound is loud. There is a pansystolic murmur at the lower left sternal edge, louder on inspiration. There is pitting oedema to the mid-shin bilaterally. [1]

In summary, these findings are consistent with severe chronic obstructive pulmonary disease with hyperinflation and cor pulmonale secondary to pulmonary hypertension." [1]

Examiner: "What is the significance of the loud P2?" — A loud pulmonary component of S2 indicates pulmonary hypertension (elevated pulmonary artery pressure closing the pulmonary valve more forcefully). In COPD this results from chronic hypoxic pulmonary vasoconstriction. Combined with the RV heave, elevated JVP, and tricuspid regurgitation, this constellation is cor pulmonale — right heart failure due to a pulmonary cause. [1]

---

Key DWE MCQ patterns

1. Spirometric diagnosis: Post-bronchodilator FEV1/FVC less than 0.70 confirms COPD. The ratio must be post-bronchodilator.
2. Best first-line maintenance therapy: LAMA or LABA (not ICS). Dual bronchodilation (LAMA/LABA) for symptomatic or exacerbating patients.
3. When to add ICS: Frequent exacerbations despite dual bronchodilation, especially blood eosinophils at least 300 — add as triple therapy. ICS monotherapy is inappropriate in COPD.
4. Oxygen target in COPD: SpO2 88-92%. Excess oxygen causes CO2 narcosis (Haldane effect + V/Q worsening).
5. Steroid duration in exacerbation: 5 days of prednisone 40 mg (REDUCE trial). Non-inferior to 14 days. [1]6. Antibiotic indications (Anthonisen): Type 1 (all 3 criteria) or Type 2 (2 of 3, especially with purulence). Amoxicillin-clavulanate covers the key pathogens.
6. NIV reduces mortality: Plant et al. — halved intubation and mortality. Know the indication (pH 7.25-7.35, PaCO2 at least 45 after standard therapy).
7. LTOT criteria: PaO2 less than 55 mmHg, or 55-59 with cor pulmonale/polycythaemia/pulmonary hypertension; at least 15 hours/day for mortality benefit (NOTT).
8. Clubbing is NOT a feature of COPD — its presence mandates searching for lung cancer, bronchiectasis, or ILD.
9. BODE index predicts mortality better than FEV1 — use it in the long case.
10. Alpha-1-antitrypsin deficiency: Panlobular basal emphysema, young age, liver disease — test serum AAT level. [1]

---

References

[1] ECLIPSE — Hurst JR, et al. Susceptibility to exacerbation in COPD. NEJM 2010. Prior exacerbation history is the strongest predictor of future exacerbations; established the frequent-exacerbator phenotype independent of GOLD stage. [2] TORCH — Calverley PMA, et al. Salmeterol/fluticasone and survival in COPD. NEJM 2007. Non-significant trend to mortality benefit (p=0.052); reduced exacerbations and improved FEV1/quality of life. [3] UPLIFT — Tashkin DP, et al. 4-year tiotropium trial. NEJM 2008. Tiotropium improved FEV1, quality of life, and reduced exacerbations; did not significantly slow FEV1 decline. [4] Plant PK, et al. Early ward-based NIV for COPD exacerbation. Lancet 2000. Halved intubation (15% vs 27%) and in-hospital mortality (10% vs 20%). [5] Bott J, et al. RCT of nasal ventilation in acute ventilatory failure due to COPD. Lancet 1993. Foundational NIV evidence. [6] Anthonisen NR, et al. Antibiotic therapy in COPD exacerbations. Ann Intern Med 1987. Defined Anthonisen criteria for antibiotic benefit. [7] NOTT — Nocturnal Oxygen Therapy Trial. Ann Intern Med 1980. Continuous oxygen superior to nocturnal; established LTOT survival benefit. [8] Niewoehner DE, et al. Systemic glucocorticoids in COPD exacerbation. NEJM 1999. Reduced treatment failure and length of stay. [9] REDUCE — Leuppi JD, et al. Short-term vs conventional glucocorticoids. JAMA 2013. 5-day course non-inferior to 14-day. [10] IMPACT — Lipson DA, et al. Single-inhaler triple vs dual therapy. NEJM 2018. Triple therapy reduced exacerbations and all-cause mortality. [11] Celli BR, et al. BODE index. NEJM 2004. Multidimensional index predicts mortality better than FEV1 alone. [12] Calverley PMA, et al. Roflumilast in COPD. Lancet 2009. PDE4 inhibitor reduces exacerbations in severe chronic bronchitis phenotype.

GOLD Report 2024; NICE NG115; TSANZ / Lung Foundation Australia COPD-X Plan; ATS/ERS Standards. [1]

References

1. [1]Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med, 2010.PMID 20843247
2. [2]Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med, 2007.PMID 17314337
3. [3]Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med, 2008.PMID 18836213
4. [4]Plant PK, Owen JL, Elliott MW Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial Lancet, 2000.PMID 10859037
5. [5]Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease Lancet, 1993.PMID 8099639
6. [6]Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease Ann Intern Med, 1987.PMID 3492164
7. [7]Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group Ann Intern Med, 1980.PMID 6776858
8. [8]Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group N Engl J Med, 1999.PMID 10379017
9. [9]Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial JAMA, 2013.PMID 23695200
10. [10]Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD N Engl J Med, 2018.PMID 29668352
11. [11]Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med, 2004.PMID 14999112
12. [12]Calverley PMA, Rabe KF, Goehring UM, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Lancet, 2009.PMID 19716961